



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

LONG QT SYNDROME

Based on review of available data, the Company may consider genetic testing to confirm a diagnosis of congenital long QT syndrome (LQTS) when signs and/or symptoms of LQTS are present but a definitive diagnosis cannot be made without genetic testing to be **eligible for coverage**** This includes:

- Individuals who do not meet the clinical criteria for LQTS (ie, those with a Schwartz score <4): but have a moderate-to-high pretest probability based on the Schwartz score and/or other clinical criteria.

Based on review of available data, the Company may consider Genetic testing of asymptomatic individuals to determine future risk of LQTS to be **eligible for coverage**** when at least one of the following is present:

- A close relative (ie, first-, second-, or third-degree relative) with a known LQTS variant; or
- A close relative diagnosed with LQTS by clinical means whose genetic status is unavailable.

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

Based on review of available data, the Company considers genetic testing for LQTS for all other situations not meeting the criteria outlined above, including but not limited to determining prognosis and/or directing therapy in patients with known LQTS to be **investigational**.*

BRUGADA SYNDROME

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider genetic testing to confirm a diagnosis of Brugada Syndrome (BrS) when signs and/or symptoms consistent with BrS are present but a definitive diagnosis cannot be made without genetic testing to be **eligible for coverage****.

Based on review of available data, the Company may consider Genetic testing of asymptomatic individuals to determine future risk of BrS when patients have a close relative (ie, first-, second-, or third-degree relative) with a known BrS variant to be **eligible for coverage****.

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers genetic testing for BrS for all other situations not meeting the criteria above to be **investigational**.*

CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider genetic testing to confirm a diagnosis of catecholaminergic polymorphic ventricular tachycardia (CPVT) when signs and/or symptoms of CPVT are present, but a definitive diagnosis cannot be made without genetic testing to be **eligible for coverage**.**

Based on review of available data, the Company may consider genetic testing of asymptomatic individuals to determine future risk of CPVT to be **eligible for coverage**** when at least one of the following criteria is present:

- A close relative (ie, first-, second-, or third-degree relative) with a known CPVT variant; or
- A close relative diagnosed with CPVT by clinical means whose genetic status is unavailable.

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers genetic testing for CPVT for all other situations not meeting the above criteria are not met to be **investigational**.*

SHORT QT SYNDROME

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider genetic testing of asymptomatic individuals to determine future risk of short QT syndrome (SQTS) when patients have a close relative (ie, first-, second- or third-degree relative) with a known SQTS variant to be **eligible for coverage**.**

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers genetic testing for SQTS for all other situations not meeting the criteria outlined above to be **investigational**.*

Policy Guidelines

Genetic testing should be performed by an expert in genetic testing and/or cardiac ion channelopathies.

Determining the pretest probability of long QT syndrome (LQTS) is not standardized. An example of a patient with a moderate-to-high pretest probability of LQTS is a patient with a Schwartz score of 2 or 3.

Signs and symptoms suggestive of Brugada syndrome (BrS) include the presence of a characteristic electrocardiographic pattern, documented ventricular arrhythmia, sudden cardiac death in a family member younger than 45 years old, a characteristic electrocardiographic pattern in a family member, inducible ventricular arrhythmias on electrophysiologic studies, syncope, or nocturnal agonal respirations. An index patient with suspected short QT syndrome (SQTS) would be expected to have a shortened (<2 standard deviation below from the mean) rate-corrected shortened QT interval (QTc). Cutoffs below 350 ms for men and 360 ms for women have been derived from population normal values (Tristani-Firouzi, 2014). The presence of a short QTc interval alone does not make the diagnosis of SQTS. Clinical history, family history, other electrocardiographic findings, and genetic testing may be used to confirm the diagnosis.

Testing Strategy

In general, testing for patients with suspected congenital LQTS, catecholaminergic polymorphic ventricular tachycardia (CPVT), or BrS should begin with a known familial variant, if one has been identified.

In cases where the family member's genetic diagnosis is unavailable, testing is available through either single-gene testing or panel testing. Panels for cardiac ion channelopathies are diagnostic test

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

panels that may fall into one of several categories: panels that include variants for a single condition; panels that include variants for multiple conditions (indicated plus nonindicated conditions); and panels that include variants for multiple conditions (clinical syndrome for which clinical diagnosis not possible).

For situations in which a relative of a proband with unexplained cardiac death or unexplained sudden cardiac arrest *or* an individual with unexplained sudden cardiac arrest is being evaluated, genetic testing may be part of a diagnostic strategy that includes a comprehensive history and physical exam and 12-lead electrocardiogram, along with exercise stress test, transthoracic echocardiography, and additional evaluation as guided by the initial studies. Studies have suggested that, in such cases, a probable diagnosis of an inherited cardiac condition can be made following a nongenetic evaluation in 50% to 80% of cases (Behr et al, 2008; Krahn et al, 2009; Kumar et al, 2013; Wong et al, 2014). If, after a comprehensive evaluation, a diagnosis of CPVT, LQTS, or BrS is suspected but not definitive (ie, if there is a moderate-to-high pretest probability of either condition), genetic testing could be considered.

Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Background/Overview

Cardiac Ion Channelopathies

Cardiac ion channelopathies result from variants in genes that code for protein subunits of the cardiac ion channels. These channels are essential to cell membrane components that open or close to allow ions to flow into or out of the cell. Regulation of these ions is essential for the maintenance of a normal cardiac action potential. This group of disorders is associated with ventricular arrhythmias

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

and an increased risk of sudden cardiac death (SCD). These congenital cardiac channelopathies can be difficult to diagnose, and the implications of an incorrect diagnosis could be catastrophic.

The prevalence of any cardiac channelopathy is still ill-defined but is thought to be between 1 in 2000 and 1 in 3000 persons in the general population. Data about the individual prevalences of long QT syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and short QT syndrome (SQTS) are presented in Table 1.

Table 1. Epidemiology of Cardiac Ion Channelopathies

| Variables | LQTS | Brugada Syndrome | CPVT | SQTS |
|----------------------------|--|------------------|---------------|--------------|
| Prevalence | 1:2000-5000 | 1:6000 | 1:7000-10,000 | Unidentified |
| Annual mortality rate | 0.3% (LQT1) 0.6% (LQT2) 0.56% (LQT3) | 4% ^a | 3.1% | Unidentified |
| Mean age at first event, y | 14 | 42 ^a | 15 | 40 |

Adapted from Modell et al (2012).

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

CPVT: catecholaminergic polymorphic ventricular tachycardia; LQTS: long QT syndrome; SQTS: short QT syndrome.

^a Type 1 electrocardiographic pattern.

Long QT Syndrome

Congenital LQTS is an inherited disorder characterized by the lengthening of the repolarization phase of the ventricular action potential, increasing the risk for arrhythmic events, such as torsades de pointes, which may, in turn, result in syncope and SCD.

Congenital LQTS usually manifests before the age of 40 years. It is estimated that more than half of the 8000 sudden unexpected deaths in children may be related to LQTS. The mortality rate of untreated patients with LQTS is estimated at 1% to 2% per year, although this figure will vary with the genotype.

Brugada Syndrome

BrS is characterized by cardiac conduction abnormalities that increase the risk of syncope, ventricular arrhythmia, and SCD. The disorder primarily manifests during adulthood, although ages between 2 days and 85 years have been reported. BrS is an autosomal dominant disorder with an unexplained male predominance. Males are more likely to be affected than females (approximate ratio, 8:1). BrS is estimated to be responsible for 12% of SCD cases. For both sexes, there is an equally high-risk of ventricular arrhythmias or sudden death. Penetrance is highly variable, with phenotypes ranging from asymptomatic expression to death within the first year of life.

Catecholaminergic Polymorphic Ventricular Tachycardia

CPVT is a rare, inherited channelopathy that may present with autosomal dominant or autosomal recessive inheritance. The disorder manifests as a bidirectional or polymorphic ventricular tachycardia precipitated by exercise or emotional stress. The prevalence of CPVT is estimated between 1 in 7000 and 1 in 10000 persons. CPVT has a mortality rate of 30% to 50% by age 35 and is responsible for 13% of cardiac arrests in structurally normal hearts. CPVT was previously believed to manifest only during childhood, but studies have now identified presentation between infancy and 40 years of age.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

Short QT Syndrome

SQTS is characterized by a shortened QT interval on the electrocardiogram and, at the cellular level, a shortening of the action potential. The clinical manifestations are an increased risk of atrial and/or ventricular arrhythmias. Because of the disease's rarity, the prevalence and risk of sudden death are currently unknown.

Sudden Cardiac Arrest or Sudden Cardiac Death

SCA and SCD refer to the sudden interruption of cardiac activity with circulatory collapse. The most common cause is coronary artery disease. Approximately 5% to 10% of SCA and SCD are due to arrhythmias without structural cardiac disease and are related to the primary electrical disease syndromes. The previously described cardiac ion channelopathies are among the primary electrical disease syndromes.

The evaluation and management of a survivor of SCA include an assessment of the circumstances of the event as well as a comprehensive physical examination emphasizing cardiovascular and neurologic systems, laboratory testing, electrocardiogram, and more advanced cardiac imaging or electrophysiologic testing as may be warranted. Genetic testing might be considered when, after completion of a comprehensive evaluation, there are findings consistent with a moderate-to-high likelihood of a primary electrical disease. Postmortem protocols for evaluation of a fatal SCA should be implemented when possible.

Genetics of Cardiac Ion Channelopathies

Long QT Syndrome

There are more than 1200 unique variants on at least 13 genes encoding potassium-channel proteins, sodium-channel proteins, calcium channel-related factors, and membrane adaptor proteins that have been associated with LQTS. In addition to single variants, some cases of LQTS are associated with deletions or duplications of genes.

The absence of a variant does not imply the absence of LQTS; it is estimated that variants are only identified in 70% to 75% of patients with a clinical diagnosis of LQTS. A negative test is only definitive when there is a known variant identified in a family member and targeted testing for this variant is negative.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

Another factor complicating interpretation of the genetic analysis is the penetrance of a given variant or the presence of multiple phenotypic expressions. For example, approximately 50% of variant carriers never have any symptoms. There is variable penetrance for the LQTS, and penetrance may differ for the various subtypes. While linkage studies in the past have indicated that penetrance was 90% or greater, a 1999 analysis using molecular genetics challenged this estimate and suggested that penetrance may be as low as 25% for some families.

Variants involving *KCNQ1*, *KCNH2*, and *SCN5A* are the most commonly detected in patients with genetically confirmed LQTS. Some variants are associated with extra-cardiac abnormalities in addition to the cardiac ion channel abnormalities. A summary of clinical syndromes associated with hereditary LQTS is shown in Table 1.

Table 1. Genetics of Long QT Syndrome

| Type | Other Names | Chromosome Locus | Mutated Gene | Ion Current(s) Affected | Associated Findings |
|-------|-------------|------------------|---|-------------------------|---------------------|
| LQT 1 | RWS | 11p15.5 | <i>KVLQT1</i> or <i>KCNQ1</i> (heterozygotes) | Potassium | |
| LQT 2 | RWS | 7q35-36 | <i>HERG</i> , <i>KCNH2</i> | Potassium | |
| LQT 3 | RWS | 3p21-24 | <i>SCN5A</i> | Sodium | |

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

| | | | | | |
|-------|--------------------------|----------------|------------------------------|----------------------------|---|
| LQT 4 | Ankyrin B syndrome | 4q25-27 | <i>ANK2, ANKB</i> | Sodium, potassium, calcium | Catecholaminergic polymorphic ventricular arrhythmias, sinus node dysfunction, AF |
| LQT 5 | RWS | 21q22.1-22.2 | <i>KCNE1</i> (heterozygotes) | Potassium | |
| LQT 6 | RWS | 21q22.1-22.2 | <i>MiRP1, KNCE2</i> | Potassium | |
| LQT 7 | Ander sen-Tawil syndrome | 17.q23.1-q24.2 | <i>KCNJ2</i> | Potassium | Episodic muscle weakness, congenital anomalies |
| LQT 8 | Timothy syndrome | 12q13.3 | <i>CACNA1C</i> | Calcium | Congenital heart defects, hand/foot syndactyly, ASD |

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

| | | | | | |
|--------|------|--------------|---|-----------|---------------------------------------|
| LQT 9 | RWS | 3p25.3 | <i>CAV3</i> | Sodium | |
| LQT 10 | RWS | 11q23.3 | <i>SCN4B</i> | Sodium | |
| LQT 11 | RWS | 7q21-q22 | <i>AKAP9</i> | Potassium | |
| LQT 12 | RWS | 20q11.21 | <i>SNTA1</i> | Sodium | |
| LQT 13 | RWS | 11q24.3 | <i>KCNJ5</i> | Potassium | |
| JLN 1 | JLNS | 11p15.5 | <i>KVLQT1</i> or <i>KCNQ1</i> (homozygotes or compound heterozygotes) | Potassium | Congenital sensorineural hearing loss |
| JLN 2 | JLNS | 21q22.1-22.2 | <i>KCNE1</i> (homozygotes or compound heterozygotes) | Potassium | Congenital sensorineural hearing loss |

Adapted from Beckmann et al (2013), Arking et al (2014), and Alders (2015).

AF: atrial fibrillation; ASD: autism spectrum disorder; LQT: long QT; JLNS: Jervell and Lange-Nielsen syndrome; RWS: Romano-Ward syndrome.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

Brugada Syndrome

BrS is typically inherited in an autosomal dominant manner with incomplete penetrance. The proportion of cases that are inherited, vs de novo variants, is uncertain. Although some have reported up to 50% of cases are sporadic, others have reported that the instance of de novo variants is very low and is estimated to be only 1% of cases.

Variants in 16 genes have been identified as causative of BrS, all of which lead to a decrease in the inward sodium or calcium current or an increase in one of the outward potassium currents. Of these, *SCN5A* is the most important, accounting for more than an estimated 20% of cases; *SCN10A* has also been implicated. The other genes are of minor significance and account together for approximately 5% of cases. The absence of a positive test does not indicate the absence of BrS, with more than 65% of cases not having an identified genetic cause. Penetrance of BrS among persons with an *SCN5A* variant is 80% when undergoing electrocardiogram with sodium-channel blocker challenge and 25% when not using the electrocardiogram challenge.

Catecholaminergic Polymorphic Ventricular Tachycardia

Variants in four genes are known to cause CPVT, and investigators believe other unidentified loci are involved as well. Currently, only 55% to 65% of patients with CPVT have an identified causative variant. Variants of the gene encoding the cardiac ryanodine receptor (*RYR2*) or to *KCNJ2* result in an autosomal dominant form of CPVT. *CASQ2* (cardiac calsequestrin) and *TRDN*-related CPVT exhibit autosomal recessive inheritance. Some have reported heterozygotes for *CASQ2* and *TRDN* variants for rare, benign arrhythmias. *RYR2* variants represent most CPVT cases (50%-55%), with *CASQ2* accounting for 1% to 2% and *TRDN* accounting for an unknown proportion of cases. The penetrance of *RYR2* variants is approximated at 83%.

An estimated 50% to 70% of patients will have the dominant form of CPVT with a disease-causing variant. Most variants (90%) to *RYR2* are missense variants, but in a small proportion of unrelated CPVT patients, large gene rearrangements or exon deletions have been reported. Additionally, nearly a third of patients diagnosed as LQTS with normal QT intervals have CPVT due to identified *RYR2* variants. Another misclassification, CPVT diagnosed as Anderson-Tawil syndrome may result in more aggressive prophylaxis for CPVT whereas a correct diagnosis can spare this treatment because Anderson-Tawil syndrome is rarely fatal.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

Short QT Syndrome

SQTS has been linked predominantly to variants in three genes (*KCNH2*, *KCNJ2*, *KCNQ1*). Variants in genes encoding alpha- and beta-subunits of the L-type cardiac calcium channel (*CACNA1C*, *CACNB2*) have also been associated with SQTS. Some individuals with SQTS do not have a variant in these genes, suggesting changes in other genes may also cause this disorder. SQTS is believed to be inherited in an autosomal dominant pattern. Although sporadic cases have been reported, patients frequently have a family history of the syndrome or SCD.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

Rationale/Source

Genetic testing is available for patients suspected of having cardiac ion channelopathies, including long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), Brugada syndrome (BrS), and short QT syndrome (SQTS). These disorders are clinically heterogeneous and may range from asymptomatic to presenting with sudden cardiac death. Testing for variants associated with these channelopathies may assist in diagnosis, risk-stratify prognosis, and/or identify susceptibility for the disorders in asymptomatic family members.

Long QT Syndrome

For individuals with suspected congenital LQTS who receive genetic testing for variants associated with congenital LQTS, the evidence includes observational studies reporting on the testing yield. The relevant outcomes are overall survival (OS), changes in reproductive decision making, and morbid events. A genetic variant can be identified in approximately 70% of those with LQTS. The clinical utility of genetic testing for LQTS is high when there is a moderate-to-high pretest probability. There is a chain of evidence to suggest that testing for variants associated with LQTS in individuals who are suspected to have these disorders, leads to improved outcomes. A definitive diagnosis of LQTS leads to treatment with β -blockers in most cases, and sometimes to treatment

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

with an implantable cardiac defibrillator (ICD). As a result, confirming the diagnosis is likely to lead to a health outcome benefit by reducing the risk for ventricular arrhythmias and sudden cardiac death. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are asymptomatic with close relative(s) with a known LQTS variant who receive genetic testing for variants associated with congenital LQTS, the evidence includes observational studies reporting on changes in management. The relevant outcomes are OS, A positive genetic test for an LQTS variant leads to treatment with β -blockers in most cases, and sometimes to treatment with an ICD and a negative test would allow family members to defer further testing. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Brugada Syndrome

For individuals with suspected BrS who receive genetic testing for variants associated with BrS, the evidence includes observational studies reporting on testing yields. The relevant outcomes are OS, changes in reproductive decision making, and morbid events. The clinical validity of testing for BrS is low: a genetic variant can only be identified in approximately 15% to 35% of BrS. BrS management changes, primarily use of ICDs, are directed by clinical symptoms. It is not clear that a genetic diagnosis in the absence of other clinical signs and symptoms leads to a change in management that improves outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are asymptomatic with a close relative(s) with a known BrS variant who receive genetic testing for variants associated with congenital BrS, the evidence includes observational studies reporting on testing yields. The relevant outcomes are OS, changes in reproductive decision making, and morbid events. BrS management changes, primarily use of ICDs, are directed by clinical symptoms. There is limited evidence on the effect of changes in management based on genetic testing in an individual with family members who have a known variant. However, a negative test would allow family members to defer further testing. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Given the limited available evidence on genetic testing for BrS, clinical input was obtained. There was a consensus among the specialty societies and academic medical centers providing clinical input

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

that genetic testing for BrS is medically necessary to establish a definitive diagnosis in patients with BrS symptoms and to evaluate family members of an individual with a known genetic variant of BrS. A review of guidelines from American and international cardiac specialty societies (American Heart Association, Heart Rhythm Society, European Heart Rhythm Association, Asia Pacific Heart Rhythm Society) was also conducted. The guidelines acknowledged that although the evidence is weak, genetic testing is recommended for both individuals with a suspected but not a definitive diagnosis of BrS and asymptomatic family members of individuals with known BrS variants.

Catecholaminergic Polymorphic Ventricular Tachycardia

For individuals with suspected CPVT who receive genetic testing for variants associated with congenital CPVT, the evidence includes observational studies reporting on testing yields. The relevant outcomes are OS, changes in reproductive decision making, and morbid events. A genetic variant can be identified in approximately 60% of CPVT patients. There is a chain of evidence to suggest that testing for variants associated with CPVT in individuals who are suspected to have these disorders. Confirming the diagnosis of CPVT is likely to lead to a health outcome benefit by initiating changes in management that reduce the risk of ventricular arrhythmias and sudden cardiac death. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are asymptomatic with a close relative(s) with a known CPVT variant who receive genetic testing for variants associated with congenital CPVT, the evidence includes observational studies reporting testing yields. The relevant outcomes are OS, changes in reproductive decision making, and morbid events. For close relatives of patients with known CPVT variants who are found to have a pathologic variant, preventive treatment can be initiated. Also, a negative test in the setting of a known familial variant should have a high negative predictive value. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Short QT Syndrome

For individuals with suspected SQTs who receive genetic testing for variants associated with SQTs, the evidence includes limited data on testing yields. The relevant outcomes are OS, changes in reproductive decision making, and morbid events. The yield of genetic testing in SQTs is not well-characterized. SQTs management changes, primarily use of ICDs, are directed by clinical symptoms. There is limited evidence on changes in management based on genetic testing in a

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

symptomatic proband without a definitive diagnosis. It is not clear that a genetic diagnosis in the absence of other clinical signs and symptoms leads to a change in management that improves outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes. For individuals who are asymptomatic with a close relative(s) with a known SQTs variant who receive genetic testing for variants associated with congenital SQTs, the evidence includes observational studies reporting on testing yields. The relevant outcomes are OS, changes in reproductive decision making, and morbid events. For patients with SQTs, management changes, primarily use of ICDs, are directed by clinical symptoms. There is limited evidence on changes in management based on genetic testing in an individual with family members who have a known variant. It is not clear that a genetic diagnosis in the absence of other clinical signs and symptoms leads to a change in management that improves outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

Given the limited available evidence on genetic testing for SQTs, clinical input was obtained. Among the specialty societies and academic medical centers providing input, there was no consensus on the use of genetic testing for variants associated with SQTs; however, there was consensus that genetic testing to predict future risk of disease in individuals with close relatives who have a known variant associated with SQTs is useful in management that may lead to improved outcomes. A review of guidelines was also conducted. The use of genetic testing for patients with suspected SQTs was not addressed in many guidelines; however, one did state that testing may be considered if a cardiologist has established a strong clinical index of suspicion. Additionally, the guidelines acknowledged that although the evidence is weak, genetic testing may be considered for asymptomatic family members of individuals with known SQTs variants.

For individuals who are asymptomatic with a close family member(s) who experienced sudden cardiac death, specific diagnosis has been made who receive genetic testing for variants associated with cardiac ion channelopathies, the evidence includes cohort studies that describe the genetic testing yield. In all studies identified, genetic testing was obtained only after a specific diagnosis was suspected based on history or ancillary testing. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 3 specialty societies (4 reviewers) and 4 academic medical centers (9 reviewers) while this policy was under review in 2015. Input was limited to the use of genetic testing for Brugada syndrome (BrS) and short QT syndrome (SQTS). There was a consensus that genetic testing for BrS is medically necessary to establish the diagnosis of BrS in an individual with a suspected but not definitive diagnosis of BrS and to evaluate family members of an individual with a known pathogenic genetic variant for BrS. There was less consensus on whether genetic testing for variants associated with SQTS is medically necessary to establish the diagnosis of SQTS in an individual with a suspected but not definitive diagnosis of SQTS, but there was consensus that testing for SQTS to evaluate family members of an individual with a known pathogenic genetic variant for SQTS is medically necessary. However, reviewers acknowledged that the rarity of SQTS somewhat limited conclusions that could be made.

Practice Guidelines and Position Statements

American Heart Association, American College of Cardiology, and the Heart Rhythm Society

The American Heart Association, American College of Cardiology, and the Heart Rhythm Society (2017) published guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Table 2 summarizes the recommendations relating to cardiac ion channelopathies.

Table 2. Recommendations for Genetic Testing in Cardiac Channelopathies

| Consensus Recommendation | COR | LOE |
|--|------------|------|
| In first-degree relatives of patients who have a causative mutation for long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, short QT syndrome, or | I (strong) | B-NR |

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

| Consensus Recommendation | COR | LOE |
|--|----------------|------|
| Brugada syndrome, genetic counseling and mutation-specific genetic testing are recommended. | | |
| In patients with clinically diagnosed long QT syndrome, genetic counseling and genetic testing are recommended. Genetic testing offers diagnostic, prognostic, and therapeutic information. | I (strong) | B-NR |
| In patients with catecholaminergic polymorphic ventricular tachycardia and with clinical VT or exertional syncope, genetic counseling and genetic testing are reasonable. Genetic testing may confirm a diagnosis; however, therapy for these patients is not guided by genotype status. | IIa (moderate) | B-NR |
| In patients with suspected or established Brugada syndrome, genetic counseling and genetic testing may be useful to facilitate cascade screening of relatives, allowing for lifestyle modification and potential treatment. | IIb (weak) | C-EO |
| In patients with short QT syndrome, genetic testing may be considered to facilitate screening of first-degree relatives. | IIb (weak) | C-EO |

B-NR: moderate level of evidence, nonrandomized studies; C-EO: consensus of expert opinion based on clinical experience; COR: class of recommendation; LOE: level of evidence; VT: ventricular tachycardia.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

Heart Rhythm Society, European Heart Rhythm Association, et al

The Heart Rhythm Society, the European Heart Rhythm Association, and the Asia Pacific Heart Rhythm Society (2013) issued an expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. The consensus statement refers to the 2011 guidelines on genetic testing for channelopathies and cardiomyopathies discussed next for the indications for genetic testing in patients affected by inherited arrhythmias and their family members and for diagnostic, prognostic, and therapeutic implications of the results of genetic testing. The 2013 consensus statement provided guidance for the evaluation of patients with idiopathic ventricular fibrillation, sudden unexplained death syndrome, and sudden unexplained death in infancy. Guidance on genetic testing for these patients was included (see Table 19). Idiopathic ventricular fibrillation is defined as a resuscitated cardiac arrest victim, preferably with documentation of ventricular fibrillation, in whom known cardiac, respiratory, metabolic, and toxicologic etiologies have been excluded through clinical evaluation.

The guidelines defined several terms related to specific types of sudden cardiac death, including sudden unexplained death syndrome, which refers to an unexplained sudden death in an individual older than one year of age, sudden arrhythmic death syndrome, which refers to a sudden unexplained death syndrome case with negative pathologic and toxicologic assessment, and sudden unexplained death in infancy, which refers to an unexplained sudden death in an individual younger than one year of age with negative pathologic and toxicologic assessment.

Table 3. Recommendations for Genetic Testing in IVF, SUDS, and SUDI

| | Consensus Recommendation | Class |
|-----|---|-------|
| IVF | Genetic testing in IVF can be useful when there is suspicion of a specific genetic disease following clinical evaluation of the IVF patient and/or family members. | IIa |
| | Genetic screening of a large panel of genes in IVF patients in whom there is no suspicion of an inherited arrhythmogenic disease after clinical evaluation should not be performed. | III |

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

| | Consensus Recommendation | Class |
|------|---|-------|
| SUDS | Collection of blood and/or suitable tissue for molecular autopsy/postmortem genetic testing is recommended in all SUDS victims. | I |
| | Genetic screening of the first-degree relatives of a SUDS victim is recommended whenever a pathogenic mutation in a gene associated with increased risk of sudden death is identified by molecular autopsy in the SUDS victim. | I |
| SUDI | Collection of blood and/or suitable tissue for molecular autopsy is recommended in all SUDI victims. | I |
| | An arrhythmia syndrome-focused molecular autopsy/postmortem genetic testing can be useful for all SUDI victims. | IIa |
| | Genetic screening of the first-degree relatives of a SUDI victim is recommended whenever a pathogenic mutation in a gene associated with increased risk of sudden death is identified by molecular autopsy in the SUDI victim. Obligate mutations carriers should be prioritized. | I |

IVF: idiopathic ventricular fibrillation; SUDI: sudden unexplained death in infancy; SUDS: sudden unexplained death syndrome.

The Heart Rhythm Society and European Heart Rhythm Association (2011) jointly published an expert consensus statement on genetic testing for channelopathies and cardiomyopathies. This document made the following specific recommendations on testing for long QT syndrome (LQTS), BrS, catecholaminergic polymorphic ventricular tachycardia (CPVT), and SQTS (see Table 4).

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

Table 4. Cardiac Ion Channelopathy Testing Recommendations

| | Consensus Recommendation | Class ^a | LOE ^b |
|------|---|--------------------|------------------|
| LQTS | <ul style="list-style-type: none"> • Comprehensive or LQT1-3 (<i>KCNQ1</i>, <i>KCNH2</i>, <i>SCN5A</i>) targeted LQTS genetic testing is recommended for any patient in whom a cardiologist has established a strong clinical index of suspicion for LQTS based on examination of the patient’s clinical history, family history, and expressed electrocardiographic (resting 12-lead ECGs and/or provocative stress testing with exercise or catecholamine infusion) phenotype. • Comprehensive or LQT1-3 (<i>KCNQ1</i>, <i>KCNH2</i>, <i>SCN5A</i>) targeted LQTS genetic testing is recommended for any asymptomatic patient with QT prolongation in the absence of other clinical conditions that might prolong the QT interval (such as electrolyte abnormalities, hypertrophy, bundle branch block, etc., ie, otherwise idiopathic) on serial 12-lead ECGs defined as QTc.480 ms (prepuberty) or.500 ms (adults). • Mutation-specific genetic testing is recommended for family members and other appropriate relatives subsequently following the identification of the LQTS-causative mutation in an index case. | I | C |
| | <ul style="list-style-type: none"> • Comprehensive or LQT1-3 (<i>KCNQ1</i>, <i>KCNH2</i>, <i>SCN5A</i>) targeted LQTS genetic testing may be considered for any asymptomatic patient | IIb | C |

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

| | Consensus Recommendation | Class ^a | LOE ^b |
|------|---|--------------------|------------------|
| | with otherwise idiopathic QTc values.460 ms (prepuberty) or.480 ms (adults) on serial 12-lead ECGs. | | |
| BrS | <ul style="list-style-type: none"> • Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the BrS-causative mutation in an index case. | I | C |
| | <ul style="list-style-type: none"> • Comprehensive or BrS1 (<i>SCN5A</i>) targeted BrS genetic testing can be useful for any patient in whom a cardiologist has established a clinical index of suspicion for BrS based on examination of the patient’s clinical history, family history, and expressed electrocardiographic (resting 12-lead ECGs and/or provocative drug challenge testing) phenotype. | IIa | C |
| | <ul style="list-style-type: none"> • Genetic testing is not indicated in the setting of an isolated type 2 or type 3 Brugada ECG pattern. | III | C |
| CPVT | <ul style="list-style-type: none"> • Comprehensive or <i>CPVT1</i> and <i>CVPT2</i> (<i>RYR2</i>, <i>CASQ2</i>) targeted CPVT genetic testing is recommended for any patient in whom a cardiologist has established a clinical index of suspicion for CPVT based on examination of the patient’s clinical history, family history, and expressed electrocardiographic phenotype during provocative | I | C |

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

| | Consensus Recommendation | Class ^a | LOE ^b |
|------|---|--------------------|------------------|
| | stress testing with cycle, treadmill, or catecholamine infusion. Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the CPVT-causative mutation in an index case. | | |
| SQTS | <ul style="list-style-type: none"> • Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the SQTS-causative mutation in an index case. | I | C |
| | <ul style="list-style-type: none"> • Comprehensive or SQT1-3 (<i>KCNH2</i>, <i>KCNQ1</i>, <i>KCNJ2</i>) targeted SQTS genetic testing may be considered for any patient in whom a cardiologist has established a strong clinical index of suspicion for SQTS based on examination of the patient’s clinical history, family history, and electrocardiographic phenotype. | IIb | C |

BrS: Brugada syndrome; CPVT: catecholaminergic polymorphic ventricular tachycardia; ECG: electrocardiogram; LOE: level of evidence; LQTS: long QT syndrome; QTc: corrected QT; SQTS: short QT syndrome.

^a Class I: “is recommended” when an index case has a sound clinical suspicion for the presence of a channelopathy with a high positive predictive value for the genetic test (>40%) with a signal-to-noise ratio of >10 and/or the test may provide diagnostic or prognostic information or may change therapeutic choices; Class IIa: “can be useful”; Class IIb: “may be considered”; Class III (“is not recommended”): The test fails to provide any additional benefit or could be harmful in the diagnostic process.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

^b Only consensus opinion of experts, case studies or standard of care.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 5.

Table 5. Summary of Key Trials

| NCT No. | Trial Name | Planned Enrollment | Completion Date |
|--------------------------|---|--------------------|-----------------|
| Ongoing | | | |
| NCT01705925 ^a | Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome | 500 | Dec 2019 |
| | | | |
| NCT02425189 | The Canadian National Long QT Syndrome Registry (LQTSREG) | 600 | Dec 2026 |
| | | | |

NCT: national clinical trial.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

^a Denotes industry-sponsored or cosponsored trial.

References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, “Genetic Testing for Cardiac Ion Channelopathies”, Policy #2.04.43, 02:2019.
2. Abriel H, Zaklyazminskaya EV. Cardiac channelopathies: genetic and molecular mechanisms. *Gene*. Mar 15 2013;517(1):1-11. PMID 23266818
3. Modell SM, Bradley DJ, Lehmann MH. Genetic testing for long QT syndrome and the category of cardiac ion channelopathies. *PLoS Curr*. 2012:e4f9995f9969e9996c9997. PMID 22872816
4. Huang MH, Marcus FI. Idiopathic Brugada-type electrocardiographic pattern in an octogenarian. *J Electrocardiol*. Apr 2004;37(2):109-111. PMID 15127377
5. Brugada R, Campuzano O, Sarquella-Brugada G, et al. Brugada Syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews*. Seattle, WA: University of Washington; 2016.
6. Tester DJ, Ackerman MJ. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. *Circulation*. Mar 8 2011;123(9):1021-1037. PMID 21382904
7. Bennett MT, Sanatani S, Chakrabarti S, et al. Assessment of genetic causes of cardiac arrest. *Can J Cardiol*. Jan 2013;29(1):100-110. PMID 23200097
8. Ackerman MJ, Marcou CA, Tester DJ. Personalized medicine: genetic diagnosis for inherited cardiomyopathies/channelopathies. *Rev Esp Cardiol*. Apr 2013;66(4):298-307. PMID 23484907
9. Wilders R. Cardiac ion channelopathies and the sudden infant death syndrome. *ISRN Cardiol*. 2012;2012:846171. PMID 23304551
10. Eddy CA, MacCormick JM, Chung SK, et al. Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome. *Heart Rhythm*. Sep 2008;5(9):1275-1281. PMID 18774102
11. Chiang CE. Congenital and acquired long QT syndrome. Current concepts and management. *Cardiology in Review*. Jul-Aug 2004;12(4):222-234. PMID 15191637
12. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. *Circulation*. Feb 2 1999;99(4):529-533. PMID 9927399
13. Beckmann BM, Wilde AA, Kaab S. Clinical utility gene card for: long-QT syndrome (types 1-13). *Eur J Hum Genet*. Oct 2013;21(10). PMID 23511927

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

14. Arking DE, Pulit SL, Crotti L, et al. Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. *Nat Genet.* Aug 2014;46(8):826-836. PMID 24952745
15. Alders M, Christiaans I. Long QT Syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews*. Seattle, WA: University of Washington; 2015.
16. Napolitano C, Priori SG, Bloise R. Catecholaminergic Polymorphic Ventricular Tachycardia. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews*. Seattle, WA: University of Washington; 2016.
17. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An update. *Circulation.* Aug 1993;88(2):782-784. PMID 8339437
18. Perrin MJ, Gollob MH. The genetics of cardiac disease associated with sudden cardiac death: a paper from the 2011 William Beaumont Hospital Symposium on molecular pathology. *J Mol Diagn.* Sep 2012;14(5):424-436. PMID 22749884
19. Wilde AA, Behr ER. Genetic testing for inherited cardiac disease. *Nat Rev Cardiol.* Oct 2013;10(10):571-583. PMID 23900354
20. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. *Circulation.* Feb 8 2005;111(5):659-670. PMID 15655131
21. Benito B, Brugada J, Brugada R, et al. Brugada syndrome. *Rev Esp Cardiol.* Nov 2009;62(11):1297-1315. PMID 19889341
22. Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. *Heart.* Jan 2003;89(1):66-70. PMID 12482795
23. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Heart Rhythm.* Aug 2011;8(8):1308-1339. PMID 21787999
24. Tristani-Firouzi M. The long and short of it: insights into the short QT syndrome. *J Am Coll Cardiol.* Apr 8 2014;63(13):1309-1310. PMID 24333498
25. Giustetto C, Di Monte F, Wolpert C, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. *Eur Heart J.* Oct 2006;27(20):2440-2447. PMID 16926178
26. Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic criteria. *J Am Coll Cardiol.* Feb 15 2011;57(7):802-812. PMID 21310316

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

27. Tester DJ, Will ML, Haglund CM, et al. Effect of clinical phenotype on yield of long QT syndrome genetic testing. *J Am Coll Cardiol.* Feb 21 2006;47(4):764-768. PMID 16487842
28. Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. *Circ Arrhythm Electrophysiol.* Feb 2009;2(1):6-15. PMID 19808439
29. Kapa S, Tester DJ, Salisbury BA, et al. Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. *Circulation.* Nov 3 2009;120(18):1752-1760. PMID 19841300
30. Refsgaard L, Holst AG, Sadjadieh G, et al. High prevalence of genetic variants previously associated with LQT syndrome in new exome data. *Eur J Hum Genet.* Aug 2012;20(8):905-908. PMID 22378279
31. Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. *Circulation.* Nov 14 2000;102(20):2509-2515. PMID 11076825
32. Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. *Heart Rhythm.* Jan 2010;7(1):33-46. PMID 20129283
33. Hu D, Barajas-Martinez H, Pfeiffer R, et al. Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. *J Am Coll Cardiol.* Jul 8 2014;64(1):66-79. PMID 24998131
34. Behr ER, Savio-Galimberti E, Barc J, et al. Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study. *Cardiovasc Res.* Jun 1 2015;106(3):520-529. PMID 25691538
35. Andorin A, Behr ER, Denjoy I, et al. Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. *Heart Rhythm.* Jun 2016;13(6):1274-1282. PMID 26921764
36. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. *Circulation.* Jul 2 2002;106(1):69-74. PMID 12093772
37. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. *J Am Coll Cardiol.* Nov 24 2009;54(22):2065-2074. PMID 19926015

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

38. Kapplinger JD, Pundi KN, Larson NB, et al. Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation. *Circ Genom Precis Med*. Feb 2018;11(2):e001424. PMID 29453246
39. Jabbari J, Jabbari R, Nielsen MW, et al. New exome data question the pathogenicity of genetic variants previously associated with catecholaminergic polymorphic ventricular tachycardia. *Circ Cardiovasc Genet*. Oct 2013;6(5):481-489. PMID 24025405
40. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. *Circulation*. Feb 15 2000;101(6):616-623. PMID 10673253
41. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. *JAMA*. Sep 15 2004;292(11):1341-1344. PMID 15367556
42. Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. *J Am Coll Cardiol*. Mar 8 2016;67(9):1053-1058. PMID 26940925
43. Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. *J Cardiovasc Electrophysiol*. Apr 2003;14(4):337-341. PMID 12741701
44. Hendriks KS, Hendriks MM, Birnie E, et al. Familial disease with a risk of sudden death: a longitudinal study of the psychological consequences of predictive testing for long QT syndrome. *Heart Rhythm*. May 2008;5(5):719-724. PMID 18452877
45. Andersen J, Oyen N, Bjorvatn C, et al. Living with long QT syndrome: a qualitative study of coping with increased risk of sudden cardiac death. *J Genet Couns*. Oct 2008;17(5):489-498. PMID 18719982
46. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. *New England Journal of Medicine*. May 8 2003;348(19):1866-1874. PMID 12736279
47. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. *Circulation*. Jan 2 2001;103(1):89-95. PMID 11136691
48. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. *N Engl J Med*. Oct 01 1998;339(14):960-965. PMID 9753711
49. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. *J Am Coll Cardiol*. Jan 23 2007;49(3):329-337. PMID 17239714
50. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. Oct 30 2017. PMID 29097320

- 51. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. Dec 2013;10(12):1932-1963. PMID 24011539

Policy History

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

- 04/03/2014 Medical Policy Committee review
- 04/23/2014 Medical Policy Implementation Committee approval. New policy.
- 01/01/2015 Coding Update
- 10/08/2015 Medical Policy Committee review
- 10/21/2015 Medical Policy Implementation Committee approval. Added INV statement that genetic testing for LQTS or CPVT is investigational for all situations when criteria are not met, rationale and references updated
- 01/07/2016 Medical Policy Committee review
- 01/22/2016 Medical Policy Implementation Committee approval. Added eligibility statements for diagnostic testing for Brugada syndrome and testing of an asymptomatic individual with a known familial variant associated with Brugada syndrome or SQTs.
- 01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes and CPT coding update
- 01/05/2017 Medical Policy Committee review
- 01/18/2017 Medical Policy Implementation Committee approval. No change to coverage.
- 01/04/2018 Medical Policy Committee review
- 01/17/2018 Medical Policy Implementation Committee approval. No change to coverage.
- 01/10/2019 Medical Policy Committee review
- 01/23/2019 Medical Policy Implementation Committee approval. No change to coverage.
- 01/03/2020 Medical Policy Committee review
- 01/08/2020 Medical Policy Implementation Committee approval. No change to coverage.
- 12/11/2020 Coding update

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

Next Scheduled Review Date: 01/2021

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2019 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

| Code Type | Code |
|------------------|---|
| CPT | 81403, 81405, 81406, 81407, 81408, 81413, 81414 Code added eff 1/1/2021: 0237U |
| HCPCS | S3861 |
| ICD-10 Diagnosis | I45.81, Q23.8, Q23.9, Q24.8, Z13.79, Z13.89 |

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Cardiac Ion Channelopathies

Policy # 00408

Original Effective Date: 04/23/2014

Current Effective Date: 01/08/2020

recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.